Bloomberg :press: on Nostr: Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet The ...
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a red-hot market hinges on it. #press
https://www.bloomberg.com/news/features/2024-11-04/ozempic-maker-novo-nordisk-s-new-obesity-drug-targets-biggest-weight-loss-yet?utm_source=press.coop
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a red-hot market hinges on it. #press
https://www.bloomberg.com/news/features/2024-11-04/ozempic-maker-novo-nordisk-s-new-obesity-drug-targets-biggest-weight-loss-yet?utm_source=press.coop